NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO) Valuation Check As Optimism Builds Before Quarterly Earnings
Halozyme Therapeutics (HALO) is drawing attention ahead of its upcoming quarterly earnings report, as analysts project earnings of $2.15 per share and revenue of $448.62 million, with estimates recently revised higher.
See our latest analysis for Halozyme Therapeutics.
Halozyme Therapeutics’ share price has climbed 11.56% over the past month and 12.99% year to date to US$79.44, while its 1 year total shareholder return of 36.28% suggests momentum has been building over a longer stretch.
If...